Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare ConferenceAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company’s leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company’s website, www.helixbiopharma.com, on September 9th, 2009. Health Workers Face Postcode Lottery for Swine Flu Vaccine, Chemist+Druggist RevealsTONBRIDGE, England - Thousands of frontline health workers in England are trapped in a postcode lottery after Department of Health (DH) guidance on swine flu vaccination has left local health chiefs confused over who is eligible for the jab. Rheumatoid Arthritis (RA) Patients Taking Enbrel Keep Working for LongerMAIDENHEAD, England - - Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotratm In RABASEL and REINACH, Switzerland - - CAPRA-2-Data Will be Used to File for US Marketing Approval Pitavastatin Demonstrates no Significant Drug-to-Drug Interaction When Administered With CYP3A4 InhibitorsBARCELONA, Spain - - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global biosimilars Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the global biosimilars market is expected to be worth US$19.4 billion by 2014, recording a CAGR of 89.1% from 2009 to 2014. The increasing demand from patients, insurers, and government agencies to reduce the costs of blockbuster biopharmaceuticals has created numerous opportunities in the global biosimilars market. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014WILMINGTON, Delaware - According to a new healthcare market research report ‘Global Top Minimally Invasive/Non Invasive Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), in 2009, the global minimally invasive/ non invasive market is estimated to be approximately $16.4 billion and is expected to reach $24.4 billion by 2014 at a CAGR of 8.3%. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III TrialsCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported that it has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). The Company also announced positive results from the final two Phase III studies of velaglucerase alfa, with both studies reaching all of their primary and secondary endpoints. MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure ProgressionNATICK, Massachusetts and BARCELONA, Spain - - Results of Landmark Heart Failure Trial Published by New England Journal of Medicine and Presented at ESC SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical CompanyAMSTERDAM - SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company. Global Biomaterials Market Worth US$58.1 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global biomaterials Market (2009-2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the total global biomaterials market is expected to be worth US$58.1 billion by 2014, growing at a CAGR of 15.0% from 2009 to 2014. The U.S. market is expected to account for nearly 42% of the total revenues. The biomaterials market today has already crossed $28 billion. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global Autoimmune Treatment Market (2009-2014)’, published by MarketsandMarkets ( www.marketsandmarkets.com), the global autoimmune treatment market is expected to be worth US$68.81 billion by 2014, with an estimated CAGR of 12.7% from 2009 to 2014. The North American market is expected to account for nearly 42% of the total revenues. Cell Biosciences Launches Unique Protein Phosphorylation Assay ServiceSANTA CLARA, California - Cell Biosciences, Inc. today launched a service program to provide phosphoprotein analysis of pre-clinical samples for pharmaceutical and biotechnology companies. Under the Cell Biosciences Focus Assay Service program, client companies receive detailed analytical information about cell signaling proteins in their specimens. This information provides insight into disease processes and aids in the development of new treatments. The service will be performed using the Cell Biosciences CB1000 system, which enables quick and quantitative analysis of critical control proteins in extremely small samples - as few as 25 cells per measurement. MarketsandMarkets: Global Biomarker Market Worth US$ 20.5 Billion by 2014WILMINGTON, Delaware - The Global Biomarker Market report analyzes the biomarker tools and services market over the period 2009-2014. The report studies the major market drivers, restraints, and opportunities for the global biomarker market; and also evaluates the major trends in the macro- and micro-markets with respect to different geographic regions. Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & DevelopmentCOPENHAGEN and OSLO - - Experienced Biopharmaceutical Executives Form new Leadership Team at Antibody Medicines Company New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-CholesterolBARCELONA - - Surveys Establish Residual Vascular Risk is Associated With Atherogenic Dyslipidemia Suggesting the Need to Reconsider Approach to Management of Lipids Blood Test May Predict Course of MSLONDON - Scientists have discovered a blood test that could predict the course of multiple sclerosis (MS), or even indicate who is likely to develop the condition after a first MS-like attack. Neuromuscular Disease Treatment Catena(R) Available in Europe on a Named Patient BasisLIESTAL, Switzerland and WEYBRIDGE, England - - Santhera and Idis Partner to Facilitate Patient Access to Friedreich’s Ataxia Drug Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology CongressMONT-SAINT-GUIBERT, Belgium - - Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary SyndromesPARIS - - SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet Data From Largest GOLD Stage II Patient Population Treated With Tiotropium Highlight the Benefits of Earlier Treatment of COPDINGELHEIM, Germany - - New UPLIFT(R) Analysis Shows Tiotropium Significantly Improves Lung Function and Quality of Life in COPD Patients With Early Stage Disease Bavarian Nordic A/S - Half Year Interim Report 2009KVISTGAARD, Denmark - Today Bavarian Nordic published the company’s half-year interim report 2009. The full financial statements are available on the company’s website: www.bavarian-nordic.com. Below is an extract of the most significant matters in the report as well as events after the balance sheet date. Drugs Eclipse Alcohol in Child Custody TestsLONDON - There has been a significant increase in parents testing positive to drugs when required to undergo a hair test in child custody cases, according to the latest figures from Trimega Laboratories (www.trimegalabs.co.uk). Wyeth’s Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell LymphomaMAIDENHEAD, England - Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL). In the European Union (EU), TORISEL is also indicated for the first-line treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors. Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A StrainsSARASOTA, Florida - Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment ToolsBOSTON, Massachusetts and CHEADLE, England - Cardea Technology, Inc. and Optasia Medical Ltd., announce plans to collaborate and configure their software tools for Vertebral Fracture Assessment, a method for evaluating vertebral fractures from images on bone densitometers, to exchange information and create reports for the management of osteoporosis. ThromboGenics NV Announces Business Update and Half Year Results 2009LEUVEN, Belgium - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009. STALLERGENES: 1st Half-Year 2009: Performance Ahead of ExpectationsPARIS - - Net Profit Up 11% - Strong Research and Investment Effort - Positive net Financial Position Medical World Recognises New Therapy for Reflux Babies (IRL)NINOVE, Belgium - 20% of parents seek medical help because of the frequent regurgitation (spitting up food) of their baby and the accompanying discomfort (crying). Reputed medical journal “Archives of Disease in Childhood” of the “British Medical Journal” group recently published the results of the clinical research project that began at the end of 2006 in the Children’s gastroenterology department of the Brussels University Hospital. Medical World Recognises New Therapy for Reflux BabiesNINOVE, Belgium - 20% of parents seek medical help because of the frequent regurgitation (spitting up food) of their baby and the accompanying discomfort (crying). Reputed medical journal “Archives of Disease in Childhood” of the “British Medical Journal” group recently published the results of the clinical research project that began at the end of 2006 in the Children’s gastroenterology department of the Brussels University Hospital. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 AuctionWELLESLEY HILLS, Massachusetts - Joseph F. Finn, Jr., C.P.A. (”Finn”), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the intellectual property offered for sale at the September 30, 2009 auction. ProFibrix Raises US $11 Million (EUR 8 Million) in Series B FinancingLEIDEN, The Netherlands and SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company’s Supervisory Board. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)KVISTGAARD, Denmark - Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine. This potential new project will have no influence on the ongoing RFP-3 BARDA (Biomedical Advanced Research and Development Authority) contract for the procurement of 20 million doses of IMVAMUNE(R) and the licensure of the current liquid-frozen formulation, but represents an additional business opportunity. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic DisordersHOERSHOLM, Denmark - - Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma’s Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug PlatformCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development. |
